Press Releases

Date Title and Summary Additional Formats
Toggle Summary Harvard Bioscience Announces Management Change
CFO Resigns to Pursue New Opportunity HOLLISTON, Mass. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced the resignation of Robert E.
View HTML
Toggle Summary Harvard Bioscience Reports Second Quarter 2018 Financial Results
-Reports record GAAP and adjusted non-GAAP revenue of $31.5 million and $31.6 million, respectively, an increase of 66% and 25%, respectively- HOLLISTON, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer
View HTML
Toggle Summary Harvard Bioscience Schedules Second Quarter 2018 Conference Call for July 26 at 4:30 PM ET
HOLLISTON, Mass. , July 19, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2018 after market trading hours on Thursday, July 26, 2018 .
View HTML
Toggle Summary Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants For Measuring Continuous Blood Glucose
PhysioTel™ Digital M0G and M1G: Designed to Improve Animal Welfare in Large Animal Models ST. PAUL, Minn. and HOLLISTON, Mass. , June 20, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) and the global leader in wireless physiologic
View HTML
Toggle Summary Harvard Bioscience Subsidiary Data Sciences International Launches Inhalation Exposure System
A Platform Designed by Pulmonary Experts to Provide Accurate, Real-Time Monitoring of Respiratory Endpoints ST. PAUL, Minn. and HOLLISTON, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc.
View HTML
Toggle Summary Harvard Bioscience Reports First Quarter 2018 Financial Results
-Reports GAAP and adjusted non-GAAP revenue of $26.8 million and $27.7 million , respectively, an increase of 48% and 15%, respectively- HOLLISTON, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), or the Company, a global developer, manufacturer and marketer of a
View HTML
Toggle Summary Harvard Bioscience Subsidiary Multi Channel Systems Launches Beta Cell Screening System for Diabetes Research, Entering New Segment of Electrophysiology Market
Multi-Electrode Array (MEA) Offers New Route for Type 2 Diabetes Drug Development and Ability to Elucidate Beta Cell Pathophysiology HOLLISTON, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Multi Channel Systems (MCS), a subsidiary of Harvard Bioscience, Inc.
View HTML
Toggle Summary Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants to Enhance Neuroscience Research
PhysioTel™ Digital L03 and L04 Designed to Improve Animal Welfare in Large Animal Models ST. PAUL, Minn. and HOLLISTON, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) and the global leader in wireless physiologic
View HTML
Toggle Summary Harvard Bioscience Schedules First Quarter 2018 Conference Call for May 2 at 4:30 PM ET
HOLLISTON, Mass. , April 23, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its first quarter 2018 after market trading hours on Wednesday, May 2, 2018 .
View HTML
Toggle Summary Harvard Bioscience Reports Fourth Quarter and Year-End 2017 Results
Third Consecutive Quarter of Top Line Organic Growth and DSI Acquisition Position Company for Further Improvements in 2018
View HTML